ClariVest Asset Management LLC boosted its stake in Parexel International Corp. (NASDAQ:PRXL) by 15.6% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 69,068 shares of the company’s stock after buying an additional 9,297 shares during the period. ClariVest Asset Management LLC’s holdings in Parexel International Corp. were worth $4,343,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PRXL. Norges Bank purchased a new position in Parexel International Corp. during the fourth quarter valued at $31,159,000. Aperio Group LLC boosted its position in Parexel International Corp. by 23.5% in the first quarter. Aperio Group LLC now owns 10,935 shares of the company’s stock valued at $686,000 after buying an additional 2,083 shares during the last quarter. Virginia Retirement System purchased a new position in Parexel International Corp. during the first quarter valued at $1,104,000. Pacad Investment Ltd. purchased a new position in Parexel International Corp. during the first quarter valued at $681,000. Finally, Ngam Advisors L.P. boosted its position in Parexel International Corp. by 14.6% in the first quarter. Ngam Advisors L.P. now owns 19,377 shares of the company’s stock valued at $1,216,000 after buying an additional 2,475 shares during the last quarter. 95.59% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Parexel International Corp. (NASDAQ:PRXL) traded up 0.39% on Friday, hitting $68.87. The stock had a trading volume of 291,544 shares. Parexel International Corp. has a 12 month low of $56.00 and a 12 month high of $71.13. The stock has a market cap of $3.66 billion, a PE ratio of 24.08 and a beta of 0.92. The company has a 50 day moving average price of $68.54 and a 200-day moving average price of $64.59.
Parexel International Corp. (NASDAQ:PRXL) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $0.94 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.93 by $0.01. The business had revenue of $538.60 million for the quarter, compared to analysts’ expectations of $532.41 million. Parexel International Corp. had a net margin of 6.44% and a return on equity of 33.29%. The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.79 EPS. On average, equities research analysts anticipate that Parexel International Corp. will post $3.92 earnings per share for the current year.
Several research analysts have recently weighed in on PRXL shares. Jefferies Group reaffirmed a “hold” rating and issued a $70.00 price target on shares of Parexel International Corp. in a report on Thursday, June 9th. Credit Suisse Group AG started coverage on shares of Parexel International Corp. in a report on Monday, June 20th. They issued an “outperform” rating and a $75.00 price target on the stock. They noted that the move was a valuation call. Robert W. Baird reaffirmed an “outperform” rating and issued a $73.00 price target on shares of Parexel International Corp. in a report on Monday, June 27th. Zacks Investment Research cut Parexel International Corp. from a “hold” rating to a “sell” rating in a research note on Thursday, June 30th. Finally, Citigroup Inc. reissued a “buy” rating and issued a $74.00 target price (up previously from $72.00) on shares of Parexel International Corp. in a research note on Tuesday, July 5th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. Parexel International Corp. has an average rating of “Hold” and a consensus price target of $71.75.
In other news, SVP Joshua Schultz sold 2,500 shares of Parexel International Corp. stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $68.64, for a total transaction of $171,600.00. Following the transaction, the senior vice president now owns 5,168 shares in the company, valued at approximately $354,731.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.70% of the company’s stock.
Parexel International Corp. Company Profile
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world.
Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Parexel International Corp. (NASDAQ:PRXL).
Receive News & Ratings for Parexel International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parexel International Corp. and related companies with MarketBeat.com's FREE daily email newsletter.